Kimberly-Clark acquires Kenvue and creates a $48.7 billion group
The group announced that it will pay a premium of 46% over the market price
by Mo.D.
Key points
Kimberly-Clark took over Kenvue for more than $40 billion, in a landmark deal that creates a group that brings together a number of iconic brands such as Tylenol, Kleenex and Band-Aid patches in its portfolio. The deal, however, comes at a complex juncture for Kenvue, which is facing Tylenol-related lawsuits, criticism from the White House, and fluctuating demand for its products.
The market immediately reacted to the news by penalising Kimberly-Clark's shares, which lost over 14%, and rewarding Kenvue's stock with a 17.5% jump.
The financial details of the transaction
The group announced that it will pay a premium of 46% over the market price to take over the former Johnson & Johnson division, which has had a turbulent year: Kenvue saw its CEO sacked in July and ended up in the crosshairs of the White House over unsubstantiated allegations that the use of Tylenol in pregnancy could be linked to cases of autism in children.
Kenvue shareholders will receive $3.50 in cash and 0.14625 Kimberly-Clark shares for each share held, for a total value of $21.01 per share, based on Friday's closing price.
The troubles of the acquired company
Kenvue had only spent a short time as an independent company: it had been spun off from Johnson & Johnson two years ago, after the US giant announced in 2021 the separation of the low-growth consumer health division from the pharmaceuticals and medical devices business. Since then, Kenvue has been in the crosshairs of activist investors, unhappy with the group's performance. So much so that Wall Street seems to foresee significant challenges for Kimberly-Clark, who is now called upon to relaunch the brand.
